Olympus’s consolidated financial results for the fiscal year ending March 2026 show net sales of \u00a5101.0 billion (up 1.3% YoY), operating profit of \u00a59.7 billion (down 40.2%), with segment-wise growth driven by endoscopy but profit decline due to lower margins and investment expenses. The dividend remains at \u00a530, continuing growth investments and shareholder returns this fiscal year.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"7733","jir_company_name":"Olympus Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-05-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/7733-20260512-01.pdf","jir_short_summary":"Olympus's consolidated financial results for the fiscal year ending March 2026 show net sales of \u00a5101.0 billion (up 1.3% YoY), operating profit of \u00a59.7 billion (down 40.2%), with segment-wise growth driven by endoscopy but profit decline due to lower margins and investment expenses. The dividend remains at \u00a530, continuing growth investments and shareholder returns this fiscal year.","jir_summary":"### Performance Overview\nFor the fiscal year ending March 2026, consolidated net sales reached \u00a5101.0 billion (up 1.3% YoY), but operating income decreased significantly to \u00a59.7 billion (down 40.2%). Segment-wise, growth in the endoscopy segment supported overall results, but net profit declined due to decreasing profit margins and investment burdens. The dividend remains at \u00a530, with ongoing focus on growth investments and shareholder returns. The company is also actively promoting R&D and M&A activities.\n\n### Future Outlook and Impact on Shareholders\nNext fiscal year's earnings forecast projects net sales of \u00a5105.5 billion to \u00a5106.0 billion, with a continued dividend of \u00a530. The strategic focus is on steady growth in the endoscopy business and ongoing investments to improve profitability and competitiveness. While maintaining shareholder returns, Olympus aims for long-term growth through R&D and M&A. Financially, efforts will be made to enhance cash flow and capital efficiency, balancing stable dividends with shareholder value improvement.","jir_financial_highlights":"Net Sales: \u00a5101.0 billion (YoY +1.3%)\nOperating Income: \u00a59.7 billion (YoY -40.2%)\nNet Income Attributable to Owners of the Parent: \u00a56.8 billion (YoY -42.2%)","jir_category":"","jir_hashtags":"#Olympus, #IRFinancialResults, #JapaneseStocks","jir_key_figures":"Net Sales: \u00a5101.0 billion (up 1.3% YoY)\nOperating Income: \u00a59.7 billion (down 40.2% YoY)\nNet Income Attributable to Owners of the Parent: \u00a56.8 billion (down 42.2% YoY)","jir_meta_title":"\u3010Olympus\u30112026 Fiscal Year Financial Results\uff5cNet Sales \u00a5101.0 billion (+1.3%)\uff5cDividend \u00a530","jir_meta_description":"Olympus's FY 2026 financial results show net sales of \u00a5101.0 billion (+1.3% YoY), profit decline, but dividend maintained at \u00a530. The report explains business strategies and future outlook.","jir_og_title":"\u3010Olympus\u30112026 Fiscal Year Financial Results\uff5cNet Sales \u00a5101.0 billion (+1.3%)","jir_og_description":"Overview of Olympus\u2019s FY 2026 financial results and future strategies. Sales increased but profits declined; shareholder returns maintained with dividend of \u00a530.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6918,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-48261","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n